Skip to main content

#151532

Anti-Factor VII [RFF-VII/2]

Cat. #151532

Anti-Factor VII [RFF-VII/2]

Cat. #: 151532

Unit size: 100 ug

Availability: 10-12 weeks

Target: Factor VII

Class: Monoclonal

Application: ELISA ; Fn ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Alison Goodall

Institute: University College London (UCL)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Factor VII [RFF-VII/2]
  • Research fields: Tissue-specific biology
  • Clone: RFF-VII/2
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; Fn ; WB
  • Description: Factor VII is a 50kDa multi-domain, single chain plasma glycoprotein synthesised in the liver. It is essential for blood coagulation. Factor VII is converted to the active, two chain, serine protease Factor VIIa via cleavage by thrombin, factor Xa, factor IXa or factor XIIa. Factor VIIa converts factor X to factor Xa, which in turn converts prothrombin to thrombin. This monoclonal antibody inhibits human FVII activity and may also be used to immunodeplete FVII from normal plasma.
  • Immunogen: Purified human Factor VII
  • Isotype: IgG1 kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Factor VII
  • Target background: Factor VII is a 50kDa multi-domain, single chain plasma glycoprotein synthesised in the liver. It is essential for blood coagulation. Factor VII is converted to the active, two chain, serine protease Factor VIIa via cleavage by thrombin, factor Xa, factor IXa or factor XIIa. Factor VIIa converts factor X to factor Xa, which in turn converts prothrombin to thrombin. This monoclonal antibody inhibits human FVII activity and may also be used to immunodeplete FVII from normal plasma.

Applications

  • Application: ELISA ; Fn ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1mg/ml
  • Unit size: 100 ug
  • Storage buffer: RPMI + 10% FCS; non-adherent; subculture every 2-3 days; split 1:5
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Takase T et al. 1988. J Clin Pathol. 41(3):337-41. PMID: 3360957 Takase T et al. 1988. J Clin Pathol. 41(3):342-5. PMID: 3360958

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.